Abstract 530P
Background
Adhesive small bowel obstruction (ASBO) is a common complication of gastrointestinal cancer surgery. Treatment includes intestinal decompression with a long intestinal tube (LIT), surgery, and hyperbaric oxygen therapy (HBOT). While the insertion of a long intestinal tube is a burdensome procedure for both patients and medical staff, HBOT has the advantage of requiring only bed rest in the device, which is less invasive. However, HBOT has not yet been reported in clinical practice. In this study, we aimed to investigate the effect of HBOT on postoperative adhesive small bowel obstruction in gastrointestinal cancer patients.
Methods
This double-center retrospective study enrolled 110 gastrointestinal cancer patients with postoperative ASBO between January 2012 and March 2023. Patients were divided into the HBOT group and the LIT group. We examined non-per os period, hospital stay, and clinical course. These factors were analyzed by propensity score matching because Hospitals A and B were located in different regions and had different hospital functions.
Results
Of 78 patients in the HBOT group and 32 patients in the LIT group, 71 (91%) and 29 (90%), respectively, responded to treatment. 7 patients in the HBOT group had a long intestinal tube inserted without improvement, and 2 of them were transferred to surgery. 2 patients had to be withdrawn due to discomfort in the HBOT device. 3 patients in the LIT group underwent surgery. Before matching, the period of non-per os was significantly shorter in the HBOT group (Mean 6.0 days, SD±3.8) than that of the LIT group (Mean 9.6 days, SD±8.0) (p<0.01). After matching, 23 patients in each group were matched. There was no significant difference in the period of non-per os between the HBOT group (Mean 8.3 days, SD±4.7) and the long intestinal tube group (Mean 9.4 days, SD±9.1).
Conclusions
HBOT for postoperative adhesive small bowel obstruction in patients with gastrointestinal is as effective as LIT therapy, and considering the patient burden, HBOT may be an effective treatment option.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.